1. Scrip
  2. >>Therapy Areas
  3. >>Dermatological

Ambitious Almirall Lays Out Ebglyss Launch Plans

 
• By Kevin Grogan

The Spanish firm is all set to launch its atopic dermatitis drug in Germany later this month and is hopeful of a smooth reimbursement path across Europe.

Mercedes Diz
Mercedes Diz • Source: Almirall

With European Commission approval for Ebglyss secured in the middle of November, Almirall SA is ready to hit the ground running with the launch of the closely watched atopic dermatitis drug in the next fortnight in Germany.

Key Takeaways
  • Partner Lilly's file for lebrikizumab was rejected in the US but Almirall is already talking reimbursement in the EU
  • Four-weekly maintenance dosing could be a key differentiator versus twice-weekly

Ebglyss (lebrikizumab), which is partnered with Eli Lilly and Company, got the thumbs-up from the Commission for patients 12 years and older with a body weight of at least 40 kg, based on three Phase III studies including ADvocate 1 and ADvocate 2, evaluating the interleukin-13 inhibitor as monotherapy, and ADhere, assessing the drug in combination with topical corticosteroids (TCS)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Dermatological

Abeona Sets $3.1m Price For Rare Skin Disorder Gene Therapy

 
• By Joseph Haas

Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.

Seven Up For Sanofi and Regeneron With Dupixent CSU Approval

 
• By Kevin Grogan

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.

Almirall Looks To Dominate Across Derma Spectrum

 
• By Kevin Grogan

CEO Carlos Gallardo tells Scrip the Barcelona-based group has laid the foundations to advance four promising assets that have considerable potential for a variety of dermatological diseases.

Incyte’s Povorcitinib Looks Approvable In HS, But How Competitive?

 
• By Joseph Haas

Incyte’s JAK1 inhibitor meets the primary endpoint in two Phase III hidradenitis suppurativa trials, but the drug may not be able to supplant established biologic therapies.

More from Therapy Areas

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.